Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer-Reference-Cited by-同舟云学术

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer

Published:2022-05-13 Issue:8 Volume:148 Page:2023-2043
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Myer Nicole M.^ORCID,Shitara Kohei,Chung Hyun C.,Lordick Florian,Kelly Ronan J.,Szabo Zsolt,Cao Z. Alexander,Leong Stephen,Ilson David H.,Weichert Wilko

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-021-03902-1.pdf

Reference139 articles.

1. Abrahao-Machado LF, Scapulatempo-Neto C (2016) HER2 testing in gastric cancer: an update. World J Gastroenterol 22(19):4619–4625

2. Arai T, Sakurai U, Sawabe M, Honma N, Aida J, Ushio Y et al (2013) Frequent microsatellite instability in papillary and solid-type, poorly differentiated adenocarcinomas of the stomach. Gastric Cancer 16(4):505–512

3. Arnold A, Daum S, von Winterfeld M, Berg E, Hummel M, Horst D et al (2019) Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry. Pathol Res Pract 215(11):152662

4. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697

5. Bartley AN, Washington MK, Ismaila N, Ajani JA (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline summary from the college of American pathologists, American society for clinical pathology, and American society of clinical oncology. J Oncol Pract 13(1):53–57

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential role of lncRNA LOXL1-AS1 in human cancer development: a narrative review;Translational Cancer Research;2024-04

2. Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma;Frontiers in Pharmacology;2023-08-31

3. Apolipoprotein C1 promotes tumor progression in gastric cancer;Oncology Research;2023

4. Zolbetuximab: An Investigational First-Line Treatment for CLDN18.2-positive, HER2-negative Gastric and Gastro-oesophageal Junction Cancer;Oncology & Haematology;2023

5. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18 .2+ gastric or gastroesophageal junction adenocarcinoma;Cancer Science;2022-12-25